Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Dermata Therapeutics Inc WT (NQ: DRMAW )

0.0148 +0.0002 (+1.37%)
Streaming Delayed Price Updated: 12:07 PM EDT, Aug 16, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 400
Open 0.0190
Bid (Size) 0.0148 (3)
Ask (Size) 0.0159 (5)
Prev. Close 0.0146
Today's Range 0.0148 - 0.0190
52wk Range 0.0070 - 0.0290
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Dermata Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results
Via ACCESSWIRE
Dermata Announces Achievement of 50% Enrollment in Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for Acne
Via ACCESSWIRE

Performance

YTD
+78.31%
+78.31%
1 Month
-24.87%
-24.87%
3 Month
-12.43%
-12.43%
6 Month
+5.71%
+5.71%
1 Year
-48.43%
-48.43%

More News

Read More
Dermata Therapeutics Announces Exercise of Warrants for $2.66 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules
Via ACCESSWIRE
Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
Via ACCESSWIRE
Dermata to Present at the Emerging Growth Conference on April 3, 2024
Via ACCESSWIRE
Dermata to Present at the Emerging Growth Conference on February 7, 2024
Via ACCESSWIRE
Why Dermata Therapeutics Stock Took Off After-Hours
Via Benzinga
Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results
Via ACCESSWIRE
Dermata Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results
Via ACCESSWIRE
Dermata Expands Global Intellectual Patent Portfolio with Issuance of Japanese Patent for DMT410 for the Treatment of Hyperhidrosis
Via ACCESSWIRE
Dermata Enrolls First Patient in Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for Acne
Via ACCESSWIRE
Dermata to Begin Enrolling Patients in DMT310 Phase 3 Acne Clinical Program in December 2023 based on Agreement with FDA on the Phase 3 Protocols
Via ACCESSWIRE
Dermata Announces Exercise of Warrants for $2.26 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules
Via ACCESSWIRE
Dermata to Present at the H.C. Wainwright 25th Annual Global Investment Conference
Via ACCESSWIRE
Dermata Therapeutics Announces $1.8 Million Offering Priced At-The-Market Under Nasdaq Rules
Via ACCESSWIRE
Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial Results
Via ACCESSWIRE
Dermata Therapeutics Provides Corporate Update and Reports Full Year 2022 Financial Results
Via ACCESSWIRE
Dermata Therapeutics Announces Positive Feedback from FDA on the DMT310 Phase 3 Clinical Development Program in Moderate-to-Severe Acne
Via ACCESSWIRE
Dermata Therapeutics to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and hosted by M-Vest on Tuesday, June 20th to Thursday, June 22nd at 9:00 A.M. ET
Via ACCESSWIRE
Journal of the American Academy of Dermatology Publishes Positive DMT310 Phase 2b Acne Results
Via ACCESSWIRE
Dermata Therapeutics Announces Closing of $1.8 Million Offering Priced At-The-Market Under Nasdaq Rules
Via ACCESSWIRE
Dermata Announces Receipt of Type C Meeting Response from the FDA and Submission of DMT310 End of Phase 2 Meeting Package
Via ACCESSWIRE
Dermata Therapeutics Announces Closing of $5.0 Million Public Offering
Via ACCESSWIRE
Dermata Therapeutics Announces Pricing of $5.0 Million Public Offering
Via ACCESSWIRE
Dermata Announces Topline Results from DMT310 Phase 2 Clinical Trial for the Treatment of Moderate-to-Severe Rosacea
Via ACCESSWIRE
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.